Meitheal Pharmaceuticalsincis A Biopharmaceutical Company Based In Chicagofounded In 2017Thecompany Specializes In Generic Injectablesspecialty Biopharmaceuticalsand Branded Productsmeitheal Is Committed To Improving Access To Affordablemedicines Through Reliablemanufacturing And Supply Chain Solutionsguided By Theprincipleof Community Collaboration Thecompany Has Achieved Significant Growthreaching $2 0 Million In Sales By 202 With 17 New Product Launches That Yearmeitheal Has A Robust Pipelinewith 18 Products In Research And Development21 Under Fda Reviewand 22 Planned Launches For 2025It Has Been Recognized For Its Rapid Growth And Workplacecultureranking2 On Crainaes Fast 50 In 2024 And Consistently Appearing On Crainaes Best Places To Work List From 2022 To 2024 Meitheal S Product Portfolio Includes Over 60 Fda Approved Injectablessuch As Heparin And Enoxaparinas Well As Branded Products Likecontepoa C And Investigational Biologicsthecompany Partners With Global Manufacturers And Serves Various Market Segmentsincluding Hospitals And Retail Pharmaciesto Enhancedrug Accessibility
